Grants per year
Fingerprint
Dive into the research topics where Christopher Darus is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Grants
- 1 Active
-
MaineHealth Cancer Care Network (MHCCN) and NCORP Activities across the Lifespan
Remick, S. C., Darus, C., Bradford, L. & Rubin, P.
08/13/19 → 07/31/24
Project: Research
-
Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: Placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39)
Moore, K. N., Bookman, M., Sehouli, J., Miller, A., Anderson, C., Scambia, G., Myers, T., Taskiran, C., Robison, K., Mäenpää, J., Willmott, L., Colombo, N., Thomes-Pepin, J., Liontos, M., Gold, M. A., Garcia, Y., Sharma, S. K., Darus, C. J., Aghajanian, C., Okamoto, A., & 8 others , Jun 10 2021, In: Journal of Clinical Oncology. 39, 17, p. 1842-1855 14 p.Research output: Contribution to journal › Article › peer-review
Open Access182 Scopus citations -
Community oncologists’ perceptions and utilization of large-panel genomic tumor testing
MCGI Working Group, Dec 2021, In: BMC Cancer. 21, 1, 1273.Research output: Contribution to journal › Article › peer-review
Open Access5 Scopus citations -
Impact of geography and travel distance on outcomes in epithelial ovarian cancer: A national cancer database analysis
Daruvala, A., Lucas, F. L., Sammon, J., Darus, C. & Bradford, L., Feb 1 2021, In: International Journal of Gynecological Cancer. 31, 2, p. 209-214 6 p.Research output: Contribution to journal › Article › peer-review
11 Scopus citations -
Patients' expectations of benefits from large-panel genomic tumor testing in rural community oncology practices
MCGI Working Group, 2021, In: JCO Precision Oncology. 5, p. 1554-1562 9 p.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma
Duska, L. R., Petroni, G. R., Varhegyi, N., Brown, J., Jelovac, D., Moore, K. N., McGuire, W. P., Darus, C., Barroilhet, L. M. & Secord, A. A., Jun 2020, In: Gynecologic Oncology. 157, 3, p. 585-592 8 p.Research output: Contribution to journal › Article › peer-review
8 Scopus citations